- Case Report
892 Views
7 Pages
Treatment of Resistant TPM3::ALK + Fusion Protein Metastatic Inflammatory Myofibroblastic Tumor with ALK Targeting and Immune Checkpoint Inhibitor Combined Therapy
- Leonardo Simonelli,
- Sebastian James Khairkhahan,
- Francesco Alessandrino,
- Elizabeth Anne Montgomery and
- Gina D’Amato
Background and Clinical Significance: Inflammatory myofibroblastic tumors (IMTs) are rare neoplasms with low metastatic potential but a high recurrence rate. Approximately 60–80% of IMTs harbor anaplastic lymphoma kinase (ALK) gene rearrangemen...
